Trial Background

This trial is the MATCH subprotocol T, sponsored by the NCI, targeting patients with progressive solid tumors, lymphomas, or multiple myeloma that harbor SMO·PTCH1 mutations. Scientific evidence indicates that the mutant signaling plays a central role in tumor growth, and the intent is to provide a new option for patients who do not respond to standard therapies.

Drug Mechanism

Vismodegib is a Hedgehog pathway inhibitor that blocks the SMO protein and suppresses cellular proliferation. The Hedgehog pathway is a critical signaling cascade involved in tissue regeneration and cancer cell growth, and constitutively active mutant SMO can drive tumor progression.

Clinical Design

Phase II, ACTIVE_NOT_RECRUITING status, initiated on 2016‑06‑20. The primary endpoints are objective response rate (ORR) and safety assessment; the population consists of patients with confirmed metastatic or relapsed cancer harboring the mutation. The trial completion date is not specified, but Phase II studies typically report results within 12‑18 months.

Differentiation from Existing Therapies

Approved agents that target SMO mutations are limited, and most current treatments rely on conventional chemotherapy or immunotherapy. Vismodegib directly blocks the mutant protein, fundamentally inhibiting tumor‑growth signaling, offering a potential new therapeutic paradigm for resistant patient cohorts.

Expected Impact

If the trial yields positive results, personalized treatment options for SMO·PTCH1 mutant cancers will expand, and the broader Hedgehog inhibitor market will receive a favorable signal. Conversely, if outcomes fall short of expectations, strategies targeting this mutation may need to be reassessed.